Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Lawmakers and experts clash over IRA drug‑pricing, Medicare Part D changes and Medicaid risks
Summary
A joint oversight hearing reviewed the Inflation Reduction Act's health provisions — including drug‑price negotiation, Part D redesign and marketplace subsidies — and analyzed effects on plan participation, federal spending and vulnerable populations.
Lawmakers and expert witnesses used a joint subcommittee hearing to assess how the Inflation Reduction Act's health provisions are affecting drug prices, Medicare Part D plans and broader coverage programs, and to consider the consequences of proposed rollbacks.
Dr. Erin Trish, co‑director of the USC Schaeffer Center for Health Policy and Economics, told the panel that the IRA's drug‑price negotiation authority and Part D redesign have created market uncertainty and higher federal spending during implementation. "We got an opaque process. We got uncertainty," Trish said, adding that an abrupt benefit redesign has contributed to insurers exiting the market.
Trish testified that the number of Part D plans fell and…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
